FDA committee votes 10-1 against Ocaliva’s full approval for PBC
A U.S. Food and Drug Administration (FDA) advisory committee voted 10-1 that Ocaliva (obeticholic acid) doesn’t have a benefit-risk profile that would support its…
News
New ABCB4 mutation deemed cause of PFIC3 in 2 unrelated girls
A new ABCB4 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 3 (PFIC3) in two unrelated Southeast Asian girls, a study…
Researchers identify pathway behind MASLD-linked mutation
A study showed that a genetic mutation associated with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, results in an…
American Liver Foundation gala to recognize biliary atresia family
The American Liver Foundation (ALF) is granting its Spirit of Giving Family Award to a U.S. family for its dedication to raising funds and…
Study offers insights into potential for vaccine for hepatitis C
Researchers have uncovered the structure of the protein complex that allows the hepatitis C virus (HCV) to infect human cells, allowing them to reproduce and…
Advanz gets suspension of decision to revoke Ocaliva EU approval
Advanz Pharma has secured a temporary suspension of a decision by the European Commission (EC) to revoke conditional approval of Ocaliva (obeticholic acid) for…
New PLEC gene mutations are likely cause of girls’ liver ailment PFIC
Scientists in Thailand have identified four new mutations in the PLEC gene as the likely cause of progressive familial intrahepatic cholestasis (PFIC) in two…
Nonprofit’s petition aims to expedite Canadian access to Rezdiffra
The Fatty Liver Alliance, a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal Pharmaceuticals to apply to Canadian…
Liver disorder most common Alagille symptom in children
Cholestasis, where the flow of the digestive fluid bile from the liver to the intestines slows or stalls, is the most common feature across…
Study details antiviral mechanisms of Atea treatment for hepatitis C
Researchers have detailed exactly how bemnifosbuvir — part of Atea Pharmaceuticals’ antiviral treatment combination for chronic hepatitis C infections — turns into the…
